Role and predictive strength of transglutaminase type 2 expression in premalignant lesions of the cervix

Modern Pathology

Volumn 24, Issue 6, 2011, Pages 855-865

  Del Nonno, Franca ^a   Pisani, Giuseppe ^b   Visca, Paolo ^c   Signore, Fabrizio ^b   Grillo, Lucia Rosalba ^b   Baiocchini, Andrea ^a   Garbuglia, Anna Rosa ^a   Sepe, Sara ^a,d   Piacentini, Mauro ^a,e   Falasca, Laura ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d ROMA TRE UNIVERSITY   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

cervical intraepithelial neoplasia; HPV; p16; pRb; TG2

Indexed keywords

PROTEIN E7; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; PROTEIN P16; RETINOBLASTOMA PROTEIN;

ARTICLE; CONTROLLED STUDY; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; OXIDATION; PAPILLOMAVIRUS INFECTION; PRECANCER; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; UTERINE CERVIX EPITHELIUM;

EID: 79957879889     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.40     Document Type: Article

References (45)

1. Bosch FX, Lorincz A, Muñoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-265. (Pubitemid 34293391)
2. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-350. (Pubitemid 37328947)
3. de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004;324:17-27. (Pubitemid 38737395)
4. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006;110:525-541. (Pubitemid 43736116)
5. Münger K, Phelps WC, Bubb V, et al. The E6 and E7 genes of human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989;63: 4417-4421. (Pubitemid 19229441)
6. Dyson N, Howley PM, Munger K, et al. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243: 934-937. (Pubitemid 19066153)
7. Fiedler M, Müller-Holzner E, Viertler HP, et al. High level HPV-16 E7 oncoprotein expression correlates with reduced pRb-levels in cervical biopsies. FASEB J 2004;18:1120-1122. (Pubitemid 39561543)
8. Jeon JH, Cho SY, Kim CW, et al. Alteration of Rb binding to HPV 18 E7 modified by transglutaminase 2 with different type of polyamines. Front Biosci 2006; 11:1540-1548.
9. Piacentini M, Fesus L. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci 2002;27:534-539. (Pubitemid 35279599)
10. Iismaa SE, Wu MJ, Nanda N, et al. GTP binding and signaling by Gh/transglutaminase II involves distinct residues in a unique GTP-binding pocket. J Biol Chem 2000;275:18259-18265. (Pubitemid 30414778)
11. Hasegawa G, Suwa M, Ichikawa Y, et al. A novel function of tissue-type transglutaminase: protein dis-ulphide isomerase. Biochem J 2003;373:793-803. (Pubitemid 36981089)
12. Piacentini M, Amendola A, Ciccosanti F, et al. Type 2 transglutaminase and cell death. Prog Exp Tumor Res 2005;38:58-74.
13. Lorand L, Graham RM. Transglutaminases: crosslink-ing enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 2003;4:140-156. (Pubitemid 36172696)
14. Facchiano F, Facchiano A, Facchiano AM. The role of transglutaminase-2 and its substrates in human diseases. Front Biosci 2006;11:1758-1773. (Pubitemid 43253392)
15. Falasca L, Iadevaia V, Ciccosanti F, et al. Transgluta-minase type II is a key element in the regulation of the anti-inflammatory response elicited by apoptotic cell engulfment. J Immunol 2005;174:7330-7340. (Pubitemid 40705703)
16. Falasca L, Farrace MG, Rinaldi A, et al. Transglutami-nase type II is involved in the pathogenesis of endotoxic shock. J Immunol 2008;180:2616-2624.
17. Amendola A, Rodolfo C, Di Caro A, et al. 'Tissue' transglutaminase expression in HIV-infected cells: an enzyme with an antiviral effect? Ann N Y Acad Sci 2001;946:108-120. (Pubitemid 33127212)
18. Lu W, Strohecker A, Ou Jh JH. Post-translational modification of the hepatitis C virus core protein by tissue transglutaminase. J Biol Chem 2001;276: 47993-47999.
19. Jeon JH, Kim IG. Role of protein modifications mediated by transglutaminase 2 in human viral diseases. Front Biosci 2006;11:221-231.
20. Jeon JH, Choi KH, Cho SY, et al. Transglutaminase 2 inhibits Rb binding of human papillomavirus E7 by incorporating polyamine. EMBO J 2003;22:5273-5282.
21. Boehm JE, Singh U, Combs C, et al. Tissue transglu-taminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb. J Biol Chem 2002;277:20127-20130. (Pubitemid 34967301)
22. Milakovic T, Tucholski J, McCoy E, et al. Intracellular localization and activity state of tissue transglutami-nase differentially impacts cell death. J Biol Chem 2004;279:8715-8722. (Pubitemid 38295927)
23. Gupta R, Srinivasan R, Nijhawan R, et al. Tissue transglutaminase 2 as a biomarker of cervical intrae-pithelial neoplasia (CIN) and its relationship to p16INK4A and nuclear factor kappaB expression. Virchows Arch 2010;456:45-51.
24. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohisto-chemical analysis. Mod Pathol 1998;11:155-168. (Pubitemid 28144151)
25. Saiki RK, Scharf S, Faloona F, et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 1985;230:1350-1354. (Pubitemid 16105164)
26. Manos MM, Ting MY, Wright DK, et al. The use of polymerase chain reaction amplification for the detection of genital papillomaviruses. Cancer Cells 1989;7:209-214.
27. Bernard HU, Chan SY, Manos MM, et al. Identification and assessment of known and novel human papillo-maviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis 1994;170:1077-1085.
28. Cobo F, Concha A, Ortiz M. Human papillomavirus (HPV) type distribution in females with abnormal cervical cytology. A correlation with histological study. Open Virol J 2009;3:60-66.
29. Moody CA, Fradet-Turcotte A, Archambault J, et al. Human papillomaviruses activate caspases upon epithelial differentiation to induce viral genome amplification. Proc Natl Acad Sci 2007;104:19541-19546.
30. Feng W, Duan X, Liu J, et al. Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions. Int J Clin Exp Pathol 2009;2:249-260.
31. Collighan RJ, Griffin M. Transglutaminase 2 cross-linking of matrix proteins: biological significance and medical applications. Amino Acids 2009;36:659-670.
32. Lesort M, Attanavanich K, Zhang J, et al. J Distinct nuclear localization and activity of tissue transgluta-minase. Biol Chem 1998;273:11991-11994. (Pubitemid 28240553)
33. Peng X, Zhang Y, Zhang H, et al. Interaction of tissue transglutaminase with nuclear transport protein im-portin-alpha3. FEBS Lett 1999;446:35-39. (Pubitemid 29127245)
34. Boehm JE, Singh U, Combs C, et al. Tissue transglu-taminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb. J Biol Chem 2002;277:20127-20130. (Pubitemid 34967301)
35. Antonyak MA, Jansen JM, Miller AM, et al. Tw o isoforms of tissue transglutaminase mediate opposing cellular fates. Proc Natl Acad Sci USA 2006;103: 18609-18614. (Pubitemid 44913458)
36. Cao L, Petrusca DN, Satpathy M, et al. Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis 2008;29: 1893-1900.
37. Gundemir S, Johnson GV. Intracellular localization and conformational state of transglutaminase 2: implications for cell death. PLoS One 2009;4:e6123.
38. Almasan A, Yin Y, Kelly RE, et al. Proc Natl Acad Sci USA 1995;92:5436-5440.
39. Haas-Kogan DA, Kogan SC, Levi D, et al. Inhibition of apoptosis by the retinoblastoma gene product. EMBO J 1995;14:461-472.
40. Mishra S, Melino G, Murphy LJ. Transglutaminase 2 kinase activity facilitates protein kinase A-induced phosphorylation of retinoblastoma protein. J Biol Chem 2007;282:18108-18115. (Pubitemid 47100203)
41. Isacson C, Kessis TD, Hedrick L, et al. Both cell proliferation and apoptosis increase with lesion grade in cervical neoplasia but do not correlate with human papillomavirus type. Cancer Res 1996;56: 669-674. (Pubitemid 26055449)
42. Krawczyk E, Suprynowicz FA, Liu X, et al. Koilocy-tosis: a cooperative interaction between the human papillomavirus E5 and E6 oncoproteins. Am J Pathol 2008;173:682-688.
43. Filiano AJ, Bailey CD, Tucholski J, et al. Transgluta-minase 2 protects against ischemic insult, interacts with HIF1beta, and attenuates HIF1 signaling. FASEB J 2008;22:2662-2675.
44. Looi ML, Mohd Dali AZ, Md Ali SA, et al. Oxidative damage and antioxidant status in patients with cervical intraepithelial neoplasia and carcinoma of the cervix. Eur J Cancer Prev 2008;17:555-560.
45. Filiano AJ, Tucholski J, Dolan PJ, et al. Transglutami-nase 2 protects against ischemic stroke. Neurobiol Dis 2010;39:334-343.